ESRA19-0365 Vectors study: primary and secondary results assessing pain relief and functional outcomes using spinal cord stimulation (SCS) with high dose (HD) stimulation parameters. (30th August 2019)

• Record Type: Journal Article
• Authors: Hatheway, J; Mangal, V; Michael, F; Binit, S; Michael, V; Kelly, M; Stromberg, K; Hendrickson, K
• Is Part Of: Regional anesthesia and pain medicine. Volume 44(2019)Supplement 1
• Page Start: A97
• Page End: A98
• Publication Date: 2019-08-30
• Subjects: Conduction anesthesia -- Periodicals; Pain medicine -- Periodicals; 617.964
• DOI: 10.1136/rapm-2019-ESRAABS2019.103
• Languages: English
• ISSNs: 1098-7339

Abstract

Abstract : Background and aims: SCS delivers energy to the spinal cord with the goal of symptom relief from chronic intractable pain. Research suggests targeting stimulation at the midline of the spinal cord, starting at the T9-T10 disc space for back pain. 1 2 Recently, the effects of high energy parameters at this target have been explored, particularly stimulation at 1000 Hz. 3 4 The Vectors study evaluates whether there is significant improvement in pain starting with HD stimulation at 1000 Hz when leads span the T9-T10 disc space. Methods: Post-market, single-arm study evaluating the efficacy of SCS (IntellisTM implantable neurostimulator) starting with HD stimulation, targeting the T9-T10 disc space following paresthesia mapping (EvolveSM workflow). Subjects with chronic intractable low-back and leg pain (VAS ≥50 mm) were enrolled. Primary endpoint: Change in overall pain (VAS) at 3-month visit compared to baseline. Results: 98 subjects completed the 3-month visit. Overall pain decreased 45.8 mm on the VAS. 87% of subjects had > 50% improvement in at least one pain domain (overall, back or leg). Benefits were observed in the ODI; 65.3% improved by at least 1 category and EQ-5D; 75.5% of subjects improved on at least one dimension and no worse in other dimensions. 70% of subjects achieved a personal activity goal and 81.6% reported therapy satisfaction. Conclusions: Vectors PM provides evidence for SCS starting with HD stimulation (the EvolveSM workflow). a statistically significant reduction in pain was achieved at 3-months follow-up. Benefits were also observed in quality of life and function. Subjects are followed through 12-months post-implant to assess sustainability of outcomes.